RED LASER DIODE SYSTEM FOR PDT

用于 PDT 的红色激光二极管系统

• 批准号: 3493213
• 负责人: DANIEL R DOIRON
• 金额: $ 5万
• 依托单位: PDT SYSTEMS
• 依托单位国家: 美国
• 财政年份: 1992
• 资助国家: 美国
• 起止时间: 1992-09-30 至 1993-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/3493213
• 关键词: biomedical equipment development; clinical biomedical equipment; disease /disorder model; fiber optics; laboratory rat; laser therapy; lasers; neoplasm /cancer photoradiation therapy; nonhuman therapy evaluation; photosensitizing agents; tin

Photodynamic Therapy (PDT) is presently undergoing extensive basic, preclinical and clinical testing for the diagnosis and treatment of cancer. Regulatory approval for the first PDT drug or photosensitizer, Photofrin, is expected in 1993. Concurrent with this is the introduction of a number of second generation photosensitizers into clinical trials in late 1992 and early 1993. These second generation photosensitizers all have red wavelength activation peaks in the 660nm to 700nm range, which corresponds to the operating range of high power red laser diodes, InGaAlP, presently under development by a number of laser diode manufactures. If these laser diodes can be efficiently coupled into larger single optical fibers, be wavelength stabilized, and provided in a small overall package, they could significantly impact the clinical application of these new PDT drugs by eliminating the need for $100,000 plus laser systems presently required. It is the aim of this Phase-I project to develop and test a Prototype high power 670nm laser diode system for the use the second generation photosensitizer, SnET2. This prototype system will include fiber optic coupling of a high power phased array diode into a 400 micron core fiber, along with wavelength selection through temperature stabilization if the laser diode. Predicted performance is over 2.0 watt of power at 670nm with 3.0nm bandwidth (FWHM). The system will be tested in a rat tumor model in conjunction with the Medical College of Ohio. In Phase II a higher power clinical prototype system will be developed with output in the 3.0 watt - 4.0 watt range, and tested with SnET2 and other second generation photosensitizers in the 660nm to 700nm range. If the system can be developed into high power (3 to 4 watts), low cost (less than $30K) and easy to use device, it could significantly increase the potential of PDT by opening the treatment up to small hospitals, outpatient surgery units and doctor's offices.

光动力疗法（PDT）目前正在进行广泛的基础， 用于癌症诊断和治疗的临床前和临床测试。 第一种PDT药物或光敏剂Photofrin的监管批准， 预计在1993年。 与此同时， 第二代光敏剂进入临床试验在1992年底， 1993年初 这些第二代光敏剂都有红色 波长激活峰在660 nm至700 nm范围内，其对应于 到目前高功率红色激光二极管InGaAlP的工作范围 由许多激光二极管制造商开发。如果这些激光 二极管可以有效地耦合到较大的单光纤中， 波长稳定，并在一个小的整体封装提供，他们可以 显著影响这些新型PDT药物的临床应用， 从而消除了目前所需的100，000美元以上的激光系统的需要。 这是第一阶段项目的目的是开发和测试一个原型高 功率670 nm半导体激光系统使用的第二代 光敏剂SnET 2。 该原型系统将包括光纤 将高功率相控阵二极管耦合到400微米芯光纤中， 沿着通过温度稳定的波长选择， 激光二极管 预测性能在670 nm处超过2.0瓦， 3.0nm带宽（FWHM）。 该系统将在2010年的大鼠肿瘤模型中进行测试。 与俄亥俄州医学院合作。 在第二阶段， 将开发临床原型系统，输出功率为3.0瓦- 4.0瓦范围内，并与SnET 2和其他第二代测试 光敏剂在660 nm至700 nm范围内。 如果系统可以 开发成高功率（3到4瓦），低成本（不到3万美元）， 易于使用的设备，它可以显着增加潜力的PDT， 向小医院、门诊手术单位开放治疗， 医生的办公室。